BioMarin Pharmaceutical Inc. (BMRN)

80.84
NASDAQ : Health Technology
Prev Close 82.36
Day Low/High 80.54 / 83.03
52 Wk Low/High 79.13 / 106.74
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 179.07M
Market Cap 14.75B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Medivation Tries to Prove Its Worth

Medivation Tries to Prove Its Worth

A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market leader candidate

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

The U.S. woke up today to the news of a "Brexit" win, which has sent global markets reeling.

BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL

BioMarin Announces Acceptance Of Late Breaking Abstract For BMN 270 At The World Federation Of Hemophilia (WFH) 2016 World Congress July 27 In Orlando, FL

Investor event to be held in Orlando following the July 27 oral presentation at the WFH meeting

BioMarin Pharmaceuticals Jumps on Takeover Talk

BioMarin Pharmaceuticals Jumps on Takeover Talk

Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

While some say Sanofi could make a bid for BioMarin, analysts aren't so convinced.

Why BioMarin (BMRN) Stock Is Lower Today

Why BioMarin (BMRN) Stock Is Lower Today

BioMarin (BMRN) stock is falling this afternoon after after the company suspended recruitment for a drug trial, but Evercore contends that investors are overreacting.

3 Drugs Stocks Driving The Industry Higher

3 Drugs Stocks Driving The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Biomarin Pharmaceutical (BMRN) Is Today's Strong On High Volume Stock

Biomarin Pharmaceutical (BMRN) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a strong on high relative volume candidate

3 Stocks Dragging In The Health Care Sector

3 Stocks Dragging In The Health Care Sector

TheStreet highlights 3 stocks pushing the health care sector lower today.

3 Health Care Stocks Pushing Sector Growth

3 Health Care Stocks Pushing Sector Growth

TheStreet highlights 3 stocks pushing the health care sector higher today.

Insider Trading Alert - SUM, KLXI And BMRN Traded By Insiders

Insider Trading Alert - SUM, KLXI And BMRN Traded By Insiders

Stocks with insider trader activity include SUM, KLXI and BMRN

The New #24 Most Shorted Nasdaq 100 Component: BioMarin Pharmaceutical

The New #24 Most Shorted Nasdaq 100 Component: BioMarin Pharmaceutical

The most recent short interest data has been released for the 05/13/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review

A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review

If you take the easy approve/reject eteplirsen options off the table (and the delay certainly indicates FDA can't make up its mind) then a compromise decision is a possibility.

3 Stocks Pulling The Drugs Industry Downward

3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.

Biogen's Hemophilia Franchise IPO Is Disappointing

The deal fails to transform the company's outlook.

BioMarin Pharmaceutical Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Monster Beverage

BioMarin Pharmaceutical Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Monster Beverage

The most recent short interest data has been released for the 04/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation

Sanofi First Quarter Shows Why It Wants but Doesn't Need Medivation

The San Francisco target rejects the $9.3 billion offer, but biotech growth and a healthy pipeline mean Sanofi isn't desperate for Medivation's cancer treatments.

Biomarin Pharmaceutical (BMRN) Lags In Post-Market Trading

Biomarin Pharmaceutical (BMRN) Lags In Post-Market Trading

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market laggard candidate

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

Sanofi Presses Medivation to Hold Talks After $9.3B Offer

The French pharmaceuticals company takes its campaign to snare the oncology specialist public.

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?

Biotech Stock Mailbag: Is There a Future for Sarepta Therapeutics?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

BioMarin Enrolls First Patient In Phase 1/2 Trial Of NAGLU Fusion Protein BMN 250 For Treatment Of MPS IIIB (Sanfilippo B Syndrome)

BioMarin Enrolls First Patient In Phase 1/2 Trial Of NAGLU Fusion Protein BMN 250 For Treatment Of MPS IIIB (Sanfilippo B Syndrome)

European Commission Grants BMN 250 Orphan Drug Designation to Treat Ultra-Rare Condition

Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals

Jim Cramer's Top Takeaways: Intel, BioMarin Pharmaceuticals

Cramer says splitting itself in two would revitalize Intel and make it attractive to investors.

Jim Cramer's 'Mad Money' Recap: This Market Is Rising No Matter What You Think

Jim Cramer's 'Mad Money' Recap: This Market Is Rising No Matter What You Think

Some people can't accept that things are improving, but that means the market will continue to go higher, Cramer says.

TheStreet Quant Rating: D+ (Sell)